Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 8/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 3/20 | 0.39 |
| ▸ | ACHE | P22303 | 3/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1972272 | 1.00 | PGR (0.45) | PGRCYP1A2MAPTCYP2C19KMT2A | |
| SCHEMBL1975857 | 1.00 | PGR (0.45) | PGRCYP1A2MAPTCYP2C19KMT2A | |
| SCHEMBL1975494 | 0.84 | CYP1A2 (0.44) | PGRCYP1A2MAPTCYP2C19KMT2A | |
| SCHEMBL1975539 | 0.83 | PDK2 (0.43) | PGRMAPTKMT2AKCNH2 | |
| SCHEMBL1975538 | 0.83 | PDK2 (0.43) | PGRMAPTKMT2AKCNH2 | |
| SCHEMBL1977203 | 0.83 | PDK2 (0.43) | PGRMAPTKMT2AKCNH2 | |
| SCHEMBL1966160 | 0.76 | CYP1A2 (0.54) | PGRCYP1A2MAPTCYP2C19KMT2A | |
| SCHEMBL1975293 | 0.70 | CYP1A2 (0.45) | PGRCYP1A2MAPTCYP2C19KMT2A | |
| SCHEMBL11032373 | 0.68 | CYP1A2 (0.54) | PGRCYP1A2MAPTCYP2C19KMT2A | |
| SCHEMBL1974580 | 0.67 | CYP1A2 (0.41) | PGRCYP1A2MAPTCYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130102604-A1 | NOVEL CYCLOPROPANE INDOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-8354443-B2 | Cyclopropane indolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20110144106-A1 | NOVEL CYCLOPROPANE INDOLINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144106-A1 | NOVEL CYCLOPROPANE INDOLINONE DERIVATIVES | GPR119, CPT1A, IRS1 | PGR 3591/4885CYP1A2 163/4885MAPT 3298/4885 |
| US-20130102604-A1 | NOVEL CYCLOPROPANE INDOLINONE DERIVATIVES | GPR119, CPT1A, IRS1 | PGR 3591/4885CYP1A2 157/4885MAPT 3247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.